Robert Emmons is a Hematology physician affiliated with University of Louisville. OpenAlex indexes 44 publications with 2,798 citations (h-index 17).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
529 S Jackson St
Louisville, KY 402023229
Telephone
502-562-4363Registry record last updated 11 Oct 2018.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20258 payments
- Astellas Pharma US IncProgram year20258 payments
- Amgen Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
54%Thalidomide Analog24.1%Revlimid64%Pomalyst36%Part D<11 patientsKinase inhibitor9.5%Brukinsa54%Bosulif46%Part D<11 patients+ 4 more classes in this area
Dermatology
18.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.2%Acyclovir100%Part D≥18 patientsAnti-infectives
13.9%Short-acting sulfonamides13.9%Sulfamethoxazole-Trimethoprim100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- What Is the Impact on Collection Efficiency with Upfront Plerixafor Administration on Day 4 Versus Day 5 Administration of Peripheral Blood Stem Cell for Autologous Patients?
Biology of Blood and Marrow Transplantation
2025 - Unveiling Immediate Pseudo-Progression with Epcoritamab in Lymphoma Treatment: Case Series Exploration
Biology of Blood and Marrow Transplantation
2024 - 683 Phase I first-in-human study on the feasibility, safety, and antitumor activity of CD4-redirected chimeric antigen receptor (CAR) T-cell therapy in patients with CD4+ T-cell malignancies (TCM)
Regular and Young Investigator Award Abstracts
2023
Similar KOLs
Other experts from the same institution or the same specialty.
James Franciosi, MD
University of Louisville
Matthew Cave, MD
University of Louisville
David Tollerud, MD
University of Louisville
Goetz Kloecker, MD
University of Louisville
Joseph Antin, MD
Harvard University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”